 Bellerophon intends to use the net proceeds from the Offerings, together with its current cash and cash equivalents, for funding its ongoing clinical trials, working capital needs and other general corporate purposes. A total of 3,365,384 shares of common stock were issued in the Offerings, which includes the full exercise of the underwriters option to purchase additional shares, at a public offering price of 13.00 per share. Jefferies LLC acted as sole book-running manager for the Underwritten Offering. 